{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:10:25Z","timestamp":1792656625443,"version":"4.5.0"},"reference-count":30,"publisher":"Wiley","issue":"21","license":[{"start":{"date-parts":[[2012,4,19]],"date-time":"2012-04-19T00:00:00Z","timestamp":1334793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>The serum tumor markers \u03b1\u2010fetoprotein (AFP), \u03b2\u2010human chorionic gonadotropin (HCG), and lactate dehydrogenase (LDH) are often measured as part of surveillance protocols in patients with stage I seminoma. In this study, the authors evaluated the utility of routine measurement of these markers in the detection of disease relapse.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Data were gathered from a prospectively maintained database of patients who underwent surveillance for stage I testicular seminoma diagnosed between 1982 and 2005 at Princess Margaret Hospital. Patients were followed on a predefined schedule with physical examination (PE), serum tumor markers, abdominopelvic computed tomography, and chest x\u2010rays. The records of patients who relapsed were examined for details of imaging and serum tumor markers throughout the period of follow\u2010up until the time of relapse.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Of the 527 patients who were managed by surveillance, 75 patients (14%) relapsed at a median follow\u2010up of 72 months. Of these, 65 patients relapsed within the first 3 years and had routine serum tumor markers measured. In total, 11 patients had abnormal tumor markers at the time of relapse (AFP, 0 patients; HCG, 6 patients; LDH, 4 patients; and HCG and LDH, 1 patient). Only 1 patient had an elevated tumor marker (LDH) before relapse, as defined by an abnormal imaging study (n = 64) or physical examination (n = 1), for which the treatment and outcome were not affected.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Serum tumor marker levels did not aid in the early diagnosis of disease relapse in patients with stage I seminoma who were managed with surveillance. The current results indicated that routine measurement of serum tumor markers can be discontinued safely in seminoma surveillance schedules. Cancer 2012. \u00a9 2012 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.27539","type":"journal-article","created":{"date-parts":[[2012,4,19]],"date-time":"2012-04-19T11:50:50Z","timestamp":1334836250000},"page":"5245-5250","source":"Crossref","is-referenced-by-count":30,"title":["Utility of serum tumor markers during surveillance for stage I seminoma"],"prefix":"10.1002","volume":"118","author":[{"given":"Danny","family":"Vesprini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Tolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Gospodarowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jewett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Sweet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Panzarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Sturgeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Sugar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Anson\u2010Cartwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padraig","family":"Warde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,4,19]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.12.025"},{"issue":"4","key":"e_1_2_6_3_2","first-page":"S435","article-title":"Management of localized seminoma, stage I\u2010II: SIU\/ICUD Consensus Meeting on Germ Cell Tumors (GCT)","volume":"78","author":"Warde P","year":"2011","journal-title":"Shanghai 2009 Urology."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.815"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22674"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604280"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.12.024"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603087"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<162::AID-CNCR22>3.0.CO;2-V"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.06905.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.4481"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.06.029"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.9.2255"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq525"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.9810"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(75)90776-1"},{"issue":"1","key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000474885","article-title":"Current status of tumor markers in testicular cancer. A practical review","volume":"21","author":"Javadpour N","year":"1992","journal-title":"Eur Urol."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.3109\/02841868409136024"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9098(199602)61:2<131::AID-JSO7>3.0.CO;2-D"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0b013e318159475d"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931015)72:8<2491::AID-CNCR2820720829>3.0.CO;2-0"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67807-X"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000078336"},{"key":"e_1_2_6_24_2","first-page":"967","article-title":"Long term outcome and cost in the management of stage I testicular seminoma","volume":"7","author":"Warde P","year":"2000","journal-title":"Can J Urol."},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000474498","article-title":"Elevated human chorionic gonadotropin concentrations in the testicular vein and in peripheral venous blood in seminoma patients. An analysis of various parameters","volume":"31","author":"Hartmann M","year":"1997","journal-title":"Eur Urol."},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37460-8"},{"issue":"2","key":"e_1_2_6_27_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000474698","article-title":"HCG\u2010positive seminoma","volume":"23","author":"Weissbach L","year":"1993","journal-title":"Eur Urol."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.08.010"},{"issue":"3","key":"e_1_2_6_29_2","first-page":"1543","article-title":"No predictive value of beta\u2010hCG in patients with stage I seminoma\u2014results of a long\u2010term follow\u2010up study after adjuvant radiotherapy","volume":"25","author":"Bruns F","year":"2005","journal-title":"Anticancer Res."},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1985.68"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1159\/000020055"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.27539","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.27539","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T09:53:34Z","timestamp":1760262814000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.27539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,19]]},"references-count":30,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1002\/cncr.27539"],"URL":"https:\/\/doi.org\/10.1002\/cncr.27539","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,19]]}}}